Rigel Pharmaceuticals Financial Statements
NASDAQ: RIGLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Rigel Pharmaceuticals revenue and earnings
In fiscal 2025, Rigel Pharmaceuticals generated $294.3 million in revenue, up 64.1% from fiscal 2024, its 2nd consecutive year of revenue growth. Net income was $367.0 million (+1999.1% year over year), for a net margin of 124.7% versus a median of -21.5% in the prior 5 years. Gross margin was 93.3% (up from 89.6%) and operating margin 42.6%.
Diluted earnings per share came in at $19.48, up from $0.99. Over the last 5 fiscal years, RIGL's revenue has grown at a 22.1% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Rigel Pharmaceuticals income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 294.28M | 179.28M | 116.88M | 120.24M | 149.24M | 108.62M | 59.29M | 44.51M | 4.48M | 20.38M |
| Revenue growth (YoY) | +64.15% | +53.38% | -2.79% | -19.43% | +37.39% | +83.21% | +33.20% | +892.62% | -78.00% | — |
| Cost of Revenue | 19.62M | 18.65M | 7.11M | 1.75M | 1.08M | 895.00K | 906.00K | 287.00K | — | — |
| Gross Profit | 274.66M | 160.63M | 109.77M | 118.49M | 148.15M | 107.73M | 58.38M | 44.22M | — | — |
| Operating Expenses | 149.19M | 136.44M | 130.26M | 174.04M | 160.65M | 136.70M | 127.47M | 116.91M | — | — |
| Research & Development | 33.30M | 23.38M | 24.52M | 60.27M | 65.24M | 60.10M | 52.88M | 46.90M | 46.27M | 63.45M |
| Selling, General & Admin | 115.90M | 113.06M | 105.74M | 112.45M | 91.89M | 76.60M | 74.59M | 70.00M | 37.83M | 20.91M |
| Operating Income | 125.47M | 24.19M | -20.49M | -55.55M | -12.50M | -28.97M | -69.09M | -72.68M | -79.62M | -69.74M |
| Interest Expense | 7.32M | 7.92M | 6.87M | 3.71M | 4.86M | 1.35M | 335.00K | — | — | — |
| Pretax Income | 121.83M | 18.37M | -25.09M | -58.57M | -17.31M | -29.74M | -66.89M | — | — | — |
| Income Tax | -245.20M | 881.00K | 0 | — | 605.00K | — | — | 0 | 0 | 0 |
| Net Income | 367.02M | 17.48M | -25.09M | -58.57M | -17.91M | -29.74M | -66.89M | -70.48M | -77.99M | -69.22M |
| Net Income growth (YoY) | +1999.08% | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | 20.40 | 0.99 | -1.44 | -3.44 | -0.11 | -0.18 | -0.40 | -0.44 | -0.62 | -0.73 |
| EPS (Diluted) | 19.48 | 0.99 | -1.44 | -3.44 | -0.11 | -0.18 | -0.40 | -0.44 | -0.62 | -0.73 |
| Shares Outstanding (Basic) | 17.99M | 17.58M | 17.40M | 17.05M | 170.49M | 168.75M | 167.40M | 160.53M | 126.32M | 94.39M |
| Shares Outstanding (Diluted) | 18.84M | 17.69M | 17.40M | 17.05M | 170.49M | 168.75M | 167.40M | 160.53M | 126.32M | 94.39M |
| EBITDA | 127.88M | 26.42M | -19.25M | -54.55M | -11.33M | -28.27M | -68.41M | -72.09M | -79.15M | -68.80M |
| Gross Margin | 93.33% | 89.60% | 93.92% | 98.55% | 99.27% | 99.18% | 98.47% | 99.36% | — | — |
| Operating Margin | 42.63% | 13.49% | -17.53% | -46.20% | -8.37% | -26.67% | -116.53% | -163.30% | -1775.56% | -342.15% |
| Net Margin | 124.72% | 9.75% | -21.47% | -48.71% | -12.00% | -27.38% | -112.83% | -158.35% | -1739.34% | -339.58% |
This table shows 10 annual periods of Rigel Pharmaceuticals's income statement, from FY 2025 back to FY 2016, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow RIGL's reporting calendar. What is a income statement?